# A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

> **NCT06001086** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 70 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Disitamb Vedotin ,pyrotinib

## Key facts

- **NCT ID:** NCT06001086
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06001086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06001086, "A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06001086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*